Treatment efficacy and patient satisfaction of ustekinumab compared with tumor necrosis factor-alpha inhibitors in Chinese patients with moderate-to-severe psoriasis: a real-world study

Bin Guo,Xiaobo Jin,Leiqiang Fan,Yanfeng Zhang,Bing Xu,Tao Yang
DOI: https://doi.org/10.1080/09546634.2024.2405554
2024-09-21
Journal of Dermatological Treatment
Abstract:Background Ustekinumab is an interleukin (IL)-12/IL-23 inhibitor for the treatment of moderate-to-severe psoriasis.
dermatology
What problem does this paper attempt to address?